Milestone Pharmaceuticals (MIST) was upgraded by Raymond James Financial, Inc. to "strong-buy".
Milestone Pharmaceuticals (MIST) is now covered by Raymond James Financial, Inc.. They set a "strong-buy" rating and a $6.00 price target on the stock.
Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT
Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)